Mycotoxins are toxic and carcinogenic metabolites produced by fungi that colonize food crops. The most agriculturally important mycotoxins known today are aflatoxins, which cause liver cancer and have also been implicated in child growth impairment and acute toxicoses; fumonisins, which have been associated with esophageal cancer (EC) and neural tube defects (NTDs); deoxynivalenol (DON) and other trichothecenes, which are immunotoxic and cause gastroenteritis; and ochratoxin A (OTA), which has been associated with renal diseases. This review describes the adverse human health impacts associated with these major groups of mycotoxins. First, we provide background on the fungi that produce these different mycotoxins and on the food crops commonly infected. Then, we describe each group of mycotoxins in greater detail, as well as the adverse effects associated with each mycotoxin and the populations worldwide at risk. We conclude with a brief discussion on estimations of global burden of disease caused by dietary mycotoxin exposure.


Article metrics loading...

Loading full text...

Full text loading...


Literature Cited

  1. Abdulrazzaq YM, Osman N, Yousif ZM, Trad O. 2004. Morbidity in neonates of mothers who have ingested aflatoxins. Ann. Trop. Paediatr. 24:145–51 [Google Scholar]
  2. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. 1994. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 264:1317–19 [Google Scholar]
  3. Allander E. 1994. Kashin-Beck disease. An analysis of research and public health activities based on a bibliography 1849–1992. Scand. J. Rheumatol. Suppl. 99:1–36 [Google Scholar]
  4. Asao T, Buchi G, Abdel-Kader M, Chang S, Wick E, Wogan GN. 1963. Aflatoxins b and g. J. Am. Chem. Soc. 85:1706–7 [Google Scholar]
  5. Autrup H, Bradley KA, Shamsuddin AK, Wakhisi J, Wasunna A. 1983. Detection of putative adduct with fluorescence characteristics identical to 2,3-dihydro-2-(7′-guanyl)-3-hydroxyaflatoxin B1 in human urine collected in Murang'a district, Kenya. Carcinogenesis 4:1193–95 [Google Scholar]
  6. Autrup H, Seremet T, Wakhisi J, Wasunna A. 1987. Aflatoxin exposure measured by urinary excretion of aflatoxin B1-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. Cancer Res. 47:3430–33 [Google Scholar]
  7. Azziz-Baumgartner E, Lindblade K, Gieseker K, Rogers HS, Kieszak S. et al. 2005. Case-control study of an acute aflatoxicosis outbreak, Kenya, 2004. Environ. Health Perspect. 113:1779–83 [Google Scholar]
  8. Beardall JM, Miller JD. 1994. Diseases in humans with mycotoxins as possible causes. See Miller & Trenholm 1994 487–569
  9. Bergsjo B, Langseth W, Nafstad I, Jansen JH, Larsen HJ. 1993. The effects of naturally deoxynivalenol-contaminated oats on the clinical condition, blood parameters, performance and carcass composition of growing pigs. VetResCommun 17:283–94 [Google Scholar]
  10. Bergsjo B, Matre T, Nafstad I. 1992. Effects of diets with graded levels of deoxynivalenol on performance in growing pigs. Zent. Vet. A 39:752–58 [Google Scholar]
  11. Bhat RV, Beedu SR, Ramakrishna Y, Munshi KL. 1989. Outbreak of trichothecene mycotoxicosis associated with consumption of mould-damaged wheat production in Kashmir Valley, India. Lancet 1:35–37 [Google Scholar]
  12. Bhat RV, Krishnamachari KA. 1977. Follow-up study of aflatoxic hepatitis in parts of western India. Indian J. Med. Res. 66:55–58 [Google Scholar]
  13. Blount WP. 1961. Turkey “x” disease. J. Br. Turkey Fed. 9:52–54 [Google Scholar]
  14. Bondy GS, Pestka JJ. 2000. Immunomodulation by fungal toxins. J. Toxicol. Environ. Health B Crit. Rev. 3:2109–43 [Google Scholar]
  15. Bressac B, Kew M, Wands J, Ozturk M. 1991. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429–31 [Google Scholar]
  16. Bui-Klimke T, Wu F. 2014. Ochratoxin A and human health risk: a review of the evidence. Crit. Rev. Food Sci. Nutr In press
  17. Bulatao-Jayme J, Almero EM, Castro MC, Jardeleza MT, Salamat LA. 1982. A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int. J. Epidemiol. 11:112–19 [Google Scholar]
  18. Campbell TC, Caedo JP Jr, Bulatao-Jayme J, Salamat L, Engel RW. 1970. Aflatoxin m1 in human urine. Nature 227:403–4 [Google Scholar]
  19. Canady RA, Coker RD, Rgan SK, Krska R, Kuiper-Goodman T. et al. 2001. Deoxynivalenol. Safety Evaluation of Certain Mycotoxins in Food JECFA 420–555 Geneva: Int. Progr. Chem. Saf., World Health Org, 56th Rep. [Google Scholar]
  20. CDC 2004. Outbreak of aflatoxin poisoning—eastern and central provinces, Kenya, January-July 2004. MMWR Morb. Mortal. Wkly. Rep. 53:790–93 [Google Scholar]
  21. Chen J-G, Egner PA, Ng D, Jacobson LP, Muñoz A. et al. 2013. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev. Res. 6:1038–45 [Google Scholar]
  22. Chen J-G, Zhu J, Parkin DM, Zhang YH, Lu JH. et al. 2006a. Trends in the incidence of cancer in Qidong, China, 1978–2002. Int. J. Cancer 119:1447–54 [Google Scholar]
  23. Chen JH, Chu YL, Cao JL, Yang ZT, Guo X, Wang ZL. 2006b. T-2 toxin induces apoptosis, and selenium partly blocks, T-2 toxin induced apoptosis in chondrocytes through modulation of the Bax/Bcl-2 ratio. Food Chem. Toxicol. 44:567–73 [Google Scholar]
  24. Chen JH, Xue S, Li S, Wang ZL, Yang H. et al. 2012. Oxidant damage in Kashin-Beck disease and a rat Kashin-Beck disease model by employing T-2 toxin treatment under selenium deficient conditions. J. Orthop. Res. 30:1229–37 [Google Scholar]
  25. Cosyns JP, Jadoul M, Squifflet JP, De Plaen JF, Ferluga D, van Ypersele de Strihou C. 1994. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy?. Kidney Int. 45:61680–88 [Google Scholar]
  26. Czakai K, Muller K, Mosesso P, Pepe G, Schulze M. et al. 2011. Perturbation of mitosis through inhibition of histone acetyltransferases: the key to ochratoxin A toxicity and carcinogenicity?. Toxicol. Sci. 122:2317–29 [Google Scholar]
  27. Eriksen GS, Alexander J. 1998. Fusarium Toxins in Cereals—A Risk Assessment Copenhagen, Den.: Nordic Counc. Minist.
  28. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127:2893–917 [Google Scholar]
  29. Fukui Y, Hoshino K, Kameyama Y, Yasui T, Toda C, Nagano H. 1987. Placental transfer of ochratoxin A and its cytotoxic effect on the mouse embryonic brain. Food Chem. Toxicol. 25:117–24 [Google Scholar]
  30. Gan LS, Skipper PL, Peng XC, Groopman JD, Chen JS. et al. 1988. Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: correlation with aflatoxin B1 intake and urinary excretion of aflatoxin m1. Carcinogenesis 9:1323–25 [Google Scholar]
  31. Gelderblom WCA, Kriek NPJ, Marasas WFO, Thiel PG. 1991. Toxicity and carcinogenicity of the Fusarium moniliforme metabolite, fumonisin B1, in rats. Carcinogenesis 12:1247–51 [Google Scholar]
  32. Gelineau-van Waes J, Starr L, Maddox J, Aleman F, Voss KA. et al. 2005. Maternal fumonisin exposure and risk for neural tube defects: mechanisms in an in vivo mouse model. Birth Defects Res. A Clin. Mol. Teratol. 73:487–97 [Google Scholar]
  33. Gilbert J, Brereton P, MacDonald S. 2001. Assessment of dietary exposure to ochratoxin A in the UK using a duplicate diet approach and analysis of urine and plasma samples. Food Addit. Contam. 18:1088–93 [Google Scholar]
  34. Gong Y, Hounsa A, Egal S, Turner PC, Sutcliffe AE. et al. 2004. Postweaning exposure to aflatoxin results in impaired child growth: a longitudinal study in Benin, West Africa. Environ. Health Perspect. 112:1334–38 [Google Scholar]
  35. Gong YY, Cardwell K, Hounsa A, Egal S, Turner PC. et al. 2002. Dietary aflatoxin exposure and impaired growth in young children from Benin and Togo: cross sectional study. BMJ 325:20–21 [Google Scholar]
  36. Gouze ME, Laffitte J, Pinton P, Dedieux G, Galinier A. et al. 2007. Effect of subacute oral doses of nivalenol on immune and metabolic defence systems in mice. Vet. Res. 38:635–46 [Google Scholar]
  37. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855–78 [Google Scholar]
  38. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L. et al. 2007. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. USA 104:2912129–34 [Google Scholar]
  39. Groopman JD, Donahue PR, Zhu JQ, Chen JS, Wogan GN. 1985. Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc. Natl. Acad. Sci. USA 82:6492–96 [Google Scholar]
  40. Groopman JD, Hall AJ, Whittle H, Hudson GJ, Wogan GN. et al. 1992a. Molecular dosimetry of aflatoxin-N7-guanine in human urine obtained in the Gambia, West Africa. Cancer Epidemiol. Biomarkers Prev. 1:221–27 [Google Scholar]
  41. Groopman JD, Kensler TW, Wild CP. 2008. Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. Annu. Rev. Public Health 29:187–203 [Google Scholar]
  42. Groopman JD, Zhu JQ, Donahue PR, Pikul A, Zhang LS. et al. 1992b. Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi autonomous region, People's Republic of China. Cancer Res. 52:45–52 [Google Scholar]
  43. Guan F, Li S, Wang ZL, Yang H, Xue S. et al. 2013. Histopathology of chondronecrosis development in knee articular cartilage in a rat model of Kashin-Beck disease using T-2 toxin and selenium deficiency conditions. Rheumatol. Int. 33:157–66 [Google Scholar]
  44. Hagelberg S, Hult K, Fuchs R. 1989. Toxicokinetics of ochratoxin A in several species and its plasma-binding properties. J. Appl. Toxicol. 9:291–96 [Google Scholar]
  45. Henry SH, Bosch FX, Troxell TC, Bolger PM. 1999. Reducing liver cancer—global control of aflatoxin. Science 286:2453–54 [Google Scholar]
  46. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. 1991. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427–28 [Google Scholar]
  47. Hughes DM, Gahl MJ, Graham CH, Grieb SL. 1999. Overt signs of toxicity to dogs and cats of dietary deoxynivalenol. J. Anim. Sci. 77:693–700 [Google Scholar]
  48. IARC 1972. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 1, Some Inorganic Substances, Chlorinated Hydrocarbons, Aromatic Amines, N-Nitroso Compounds, and Natural Products: Summary of Data Reported and Evaluation Lyron, Fr.: WHO [Google Scholar]
  49. IARC 1993. IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 56. Some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins Lyon, Fr.: WHO [Google Scholar]
  50. Iverson F, Armstrong C, Nera E, Truelove J, Fernie S. et al. 1995. Chronic feeding study of deoxynivalenol in B6C3F1 male and female mice. Teratog. Carcinog. Mutagen. 15:283–306 [Google Scholar]
  51. Jackson PE, Qian GS, Friesen MD, Zhu YR, Lu P. et al. 2001. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res. 61:33–35 [Google Scholar]
  52. Jackson PE, Kuang SY, Wang JB, Strickland PT, Munoz A. et al. 2003. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis 24:1657–63 [Google Scholar]
  53. JECFA 1998. Safety Evaluation of Certain Food Additives and Contaminants: WHO Food Additive Series 40 Geneva: WHO
  54. JECFA 2002. Evaluation of certain mycotoxins in food: 56th report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Tech. Rep. Ser. 906:42–51 [Google Scholar]
  55. JECFA 2011a. Evaluation of certain contaminants in food: 72nd report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Tech. Rep. Ser. 959:37–48 [Google Scholar]
  56. JECFA 2011b. Evaluation of certain food additives and contaminants: 74th report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Tech. Rep. Ser. 966:1–125 [Google Scholar]
  57. Jiang Y, Jolly PE, Ellis WO, Wang JS, Phillips TD, Williams JH. 2005. Aflatoxin B1 albumin adduct levels and cellular immune status in Ghanaians. Int. Immunol. 17:807–14 [Google Scholar]
  58. Joffe AZ. 1978. Fusarium poae and F. sporotichiodes as principal causal agents of alimentary toxic aleukia. Mycotoxic Fungi, Mycotoxins,Mycotoxicoses: An Encylcopedic Handbook TD Wyllie, LG Morehouse 21–86 New York: Dekker [Google Scholar]
  59. Kabak B, Dobson ADW, Var I. 2006. Strategies to prevent mycotoxin contamination of food and animal feed: a review. Crit. Rev. Food Sci. Nutr. 46:593–619 [Google Scholar]
  60. Kang P, Yao Y, Yang J, Shen B, Zhou Z, Pei F. 2013. An animal model of Kashin-Beck disease induced by a low-nutrition diet and exposure to T-2 toxin. Osteoarthr. Cartil. 21:1108–15 [Google Scholar]
  61. Khlangwiset P, Wu F. 2010. Costs and efficacy of public health interventions to reduce aflatoxin-induced human disease. Food Addit. Contam. 27:998–1014 [Google Scholar]
  62. Khlangwiset P, Shephard GS, Wu F. 2011. Aflatoxins and growth impairment: a review. Crit. Rev. Toxicol. 41:740–55 [Google Scholar]
  63. Kirk GD, Camus-Randon AM, Mendy M, Goedert JJ, Merle P. et al. 2000. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from the Gambia. J. Natl. Cancer Inst. 92:148–53 [Google Scholar]
  64. Krishnamachari KA, Bhat RV, Nagarajan V, Tilak TB. 1975. Hepatitis due to aflatoxicosis. an outbreak in western India. Lancet 1:1061–63 [Google Scholar]
  65. Krogh P, Axelsen NH, Elling F, Gyrd-Hansen N, Hald B. et al. 1974. Experimental porcine nephropathy. Changes of renal function and structure induced by ochratoxin A-contaminated feed. Acta Pathol. Microbiol. Scand. Suppl. 1994:2461–21 [Google Scholar]
  66. Kubosaki A, Aihara M, Park BJ, Sugiura Y, Shibutani M. et al. 2008. Immunotoxicity of nivalenol after subchronic dietary exposure to rats. Food Chem. Toxicol. 46:253–58 [Google Scholar]
  67. Kuiper-Goodman T. 1994. Prevention of human mycotoxicoses through risk assessment and risk management. Mycotoxins in Grain JD Miller, HL Trenholm 439–69 St. Paul, MN: Eagan [Google Scholar]
  68. Lancaster MC, Jenkins FP, Philp JM. 1961. Toxicity associated with certain samples of groundnuts. Nature 192:1095–96 [Google Scholar]
  69. Lewis L, Onsongo M, Njapau H, Schurz-Rogers H, Luber G. et al. 2005. Aflatoxin contamination of commercial maize products during an outbreak of acute aflatoxicosis in eastern and central Kenya. Environ. Health Perspect. 113:1763–67 [Google Scholar]
  70. Li FQ, Li YW, Luo XY, Yoshizawa T. 2002. Fusarium toxins in wheat from an area in Henan Province, PR China, with a previous human red mould intoxication episode. Food Addit. Contam. 19:163–67 [Google Scholar]
  71. Li SY, Cao JL, Shi ZL, Chen JH, Zhang ZT. et al. 2008. Promotion of the articular cartilage proteoglycan degradation by T-2 toxin and selenium protective effect. J. Zhejiang Univ. Sci. B 9:22–33 [Google Scholar]
  72. Liu Y, Chang CC, Marsh GM, Wu F. 2012. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur. J. Cancer 48:2125–36 [Google Scholar]
  73. Liu Y, Wu F. 2010. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ. Health Perspect. 118:818–24 [Google Scholar]
  74. Lu M, Cao J, Liu F, Li S, Chen J. et al. 2012. The effects of mycotoxins and selenium deficiency on tissue-engineered cartilage. Cells Tissues Organs 196:241–50 [Google Scholar]
  75. Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH. et al. 1997. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res. 57:3471–77 [Google Scholar]
  76. Luo X. 1994. Food poisoning caused by Fusarium toxins. Proceedings of the Second Asian Conference on Food Safety ILSI 129–36 Thailand: Text J. Publ. Co., Ltd.
  77. Lye MS, Ghazali AA, Mohan J, Alwin N, Nair RC. 1995. An outbreak of acute hepatic encephalopathy due to severe aflatoxicosis in Malaysia. Am. J. Trop. Med. Hyg. 53:68–72 [Google Scholar]
  78. Mahdavi R, Nikniaz L, Arefhosseini SR, Vahed Jabbari M. 2010. Determination of aflatoxin M1 in breast milk samples in Tabriz–Iran. Matern. Child Health J. 14:141–45 [Google Scholar]
  79. Marasas WFO, Kellerman TS, Gelderblom WCA, Coetzer JAW, Thiel PG, van der Lugt JJ. 1988. Leukoencephalomalacia in a horse induced by fumonisin B1, isolated from. Fusarium moniliforme. Onderstepoort J. Vet. Res 55:197–203 [Google Scholar]
  80. Marasas WFO, Riley RT, Hendricks KA, Stevens VL, Sadler TW. et al. 2006. Exposure to fumonisins and the occurrence of neural tube defects along the Texas–Mexico border. Environ. Health Perspect. 114:2237–41 [Google Scholar]
  81. Miller JD, Trenholm HL. 1994. Mycotoxins in Grain: Compounds Other than Aflatoxin. St. Paul, MN: Eagan
  82. Missmer SA, Cabrera J, Torres O, Gelderblom WCA, Allegood J. et al. 2004. Fumonisins disrupt sphingolipid metabolism, folate transport, and neural tube development in embryo culture and in vivo: a potential risk factor for human neural tube defects among populations consuming fumonisin-contaminated maize. J. Nutrition 134:711–16 [Google Scholar]
  83. Nascimento J, Nunes VA, Guedes RMC, Rachid MA. 2001. T-2 toxin and disturbed endochondral bone growth in broiler chicken. Arquivo Brasileiro Med. Vet. Zootecnia 53:332–40 [Google Scholar]
  84. National Toxicology Program (NTP) 1989. Toxicology and carcinogenesis studies of ochratoxin A (CAS No. 303-47-9) in F344/N rats (gavage studies). Natl. Toxicol. Program Tech. Rep. Ser. 358:1–142 [Google Scholar]
  85. Nejdfors P, Ekelund M, Jeppsson B, Westrom BR. 2000. Mucosal in vitro permeability in the intestinal tract of the pig, the rat, and man: species- and region-related differences. Scand. J. Gastroenterol. 35:501–7 [Google Scholar]
  86. Nesbitt BF, O'Kelly J, Sargeant K, Sheridan A. 1962. Aspergillus flavus and turkey x disease. Toxic metabolites of Aspergillus flavus. Nature 195:1062–63 [Google Scholar]
  87. Ngindu A, Johnson BK, Kenya PR, Ngira JA, Ocheng DM. et al. 1982. Outbreak of acute hepatitis caused by aflatoxin poisoning in kenya. Lancet 1:1346–48 [Google Scholar]
  88. Ohtsubo K, Ryu JC, Nakamura K, Izumiyama N, Tanaka T. et al. 1989. Chronic toxicity of nivalenol in female mice: a 2-year feeding study with Fusarium nivale Fn 2B-moulded rice. Food Chem. Toxicol. 27:591–98 [Google Scholar]
  89. Okoth SA, Ohingo M. 2004. Dietary aflatoxin exposure and impaired growth in young children from Kisumu District, Kenya: cross sectional study. Afr. J. Health Sci. 11:43–54 [Google Scholar]
  90. Osweiler GD, Ross PF, Wilson TM, Nelson PE, Witte ST. et al. 1992. Characterization of an epizootic of pulmonary edema in swine associated with fumonisin in corn screenings. J. Vet. Diagn. Investig. 4:53–59 [Google Scholar]
  91. Ozturk M. 1991. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338:1356–59 [Google Scholar]
  92. Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J. Clin. 55:74–108 [Google Scholar]
  93. Peers FG, Linsell CA. 1977. Dietary aflatoxins and human primary liver cancer. Ann. Nutr. Aliment. 31:1005–17 [Google Scholar]
  94. Pestka JJ. 2010a. Deoxynivalenol-induced proinflammatory gene expression: mechanisms and pathological sequelae. Toxins (Basel) 2:1300–17 [Google Scholar]
  95. Pestka JJ. 2010b. Toxicological mechanisms and potential health effects of deoxynivalenol and nivalenol. World Mycotoxin J. 3:323–47 [Google Scholar]
  96. Pestka JJ, Lin WS, Miller ER. 1987. Emetic activity of the trichothecene 15-acetyldeoxynivalenol in swine. Food Chem. Toxicol.: Int. J. Published Br. Ind. Biol. Res. Assoc. 25855–58 [Google Scholar]
  97. Pestka JJ, Smolinski AT. 2005. Deoxynivalenol: toxicology and potential effects on humans. J. Toxicol. Environ. Health B Crit. Rev. 8:39–69 [Google Scholar]
  98. Pfohl-Leszkowicz A, Manderville RA. 2007. Ochratoxin A: an overview on toxicity and carcinogenicity in animals and humans. Mol. Nutr. Food Res. 51:161–99 [Google Scholar]
  99. Pieters MN, Freijer J, Baars BJ, Fiolet DC, van Klaveren J, Slob W. 2002. Risk assessment of deoxynivalenol in food: concentration limits, exposure and effects. Adv. Exp. Med. Biol. 504:235–48 [Google Scholar]
  100. Probst C, Njapau H, Cotty PJ. 2007. Outbreak of an acute aflatoxicosis in Kenya in 2004: identification of the causal agent. Appl. Environ. Microbiol. 73:2762–64 [Google Scholar]
  101. Pronk M, Schothorst R, Egmond Hv. 2002. Toxicology and occurrence of nivalenol, fusarenon X, diacetoxyscirpenol, neosolaniol and 3- and 15- acetyldeoxynivalenol; a review of six trichothecenes RIVM Rep. 388802024, Natl. Inst. Public Health Environ, Bilthoven, Neth. http://www.rivm.nl/en/Documents_and_publications/Scientific/Reports/2002/november/Toxicology_and_occurrence_of_nivalenol_fusarenon_X_diacetoxyscirpenol_neosolaniol_and_3_and_15_acetyldeoxynivalenol_a_review_of_six_trichothecenes?sp=cml2bXE9ZmFsc2U7c2VhcmNoYmFzZT01MTk3MDtyaXZtcT1mYWxzZTs=&pagenr=5198
  102. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT. et al. 1994. A follow-up-study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev. 3:3–10 [Google Scholar]
  103. Ricci K, Girosi F, Tarr P, Lim Y, Mason C. et al. 2006. Reducing stunting among children: the potential contribution of diagnostics. Nature 444:29–38 [Google Scholar]
  104. Ringot D, Chango A, Schneider YJ, Larondelle Y. 2006. Toxicokinetics and toxicodynamics of ochratoxin A, an update. Chem. Biol. Interact. 159:118–46 [Google Scholar]
  105. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS. et al. 1992. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339:943–46 [Google Scholar]
  106. Rotter BA, Thompson BK, Prelusky DB, Trenholm HL, Stewart B, Miller JD, Savard ME. 1996. Response of growing swine to dietary exposure to pure fumonisin B1 during an eight-week period: growth and clinical parameters. Nat. Toxins 4:42–50 [Google Scholar]
  107. Ryu J-C, Ohtsubo K, Izumiyama N, Nakamura K, Tanaka T. et al. 1988. The acute and chronic toxicities of nivalenol in mice. Fundam. Appl. Toxicol. 11:38–47 [Google Scholar]
  108. Sadeghi N, Oveisi M, Jannat B, Hajimahmoodi M, Bonyani H, Jannat F. 2009. Incidence of aflatoxin M 1 in human breast milk in Tehran, Iran. Food Control 20:75–78 [Google Scholar]
  109. Sargeant K, Sheridan A, O'Kelly J, Carnaghan RBA. 1961. Toxicity associated with certain samples of groundnuts. Nature 192:1096–97 [Google Scholar]
  110. SCF 2002. Opinion of the Scientific Committee on Food on Fusarium toxins. Part 6: Group evaluation of T-2 toxin, HT-2 toxin, nivalenol and deoxynivalenol SCF Rep. SCF/CS/CNTM/MYC/27, Eur. Comm., Brussels, Belg. http://ec.europa.eu/food/fs/sc/scf/out123_en.pdf
  111. Shank RC, Bourgeois CH, Keschamras N, Chandavimol P. 1971. Aflatoxins in autopsy specimens from Thai children with an acute disease of unknown aetiology. Food Cosmet Toxicol. 9:501–7 [Google Scholar]
  112. Shephard G, Marasas W, Burger H, Somdyala N, Rheeder J, Van der Westhuizen L. et al. 2007. Exposure assessment for fumonisins in the former Transkei region of South Africa. Food Addit. Contam. 24:6621–29 [Google Scholar]
  113. Shephard GS, Marasas WF, Yazdanpanah H, Rahimian H, Safavi N. et al. 2002. Fumonisin B1 in maize harvested in Iran during 1999. Food Addit. Contam. 19:7676–79 [Google Scholar]
  114. Shuaib FM, Jolly PE, Ehiri JE, Yatich N, Jiang Y. et al. 2010. Association between birth outcomes and aflatoxin B1 biomarker blood levels in pregnant women in Kumasi, Ghana. Trop. Med. Int. Health 15:160–67 [Google Scholar]
  115. Sidransky D, Hollstein M. 1996. Clinical implications of the p53 gene. Annu. Rev. Med. 47:285–301 [Google Scholar]
  116. Starkey DE, Ward TJ, Aoki T, Gale LR, Kistler HC. et al. 2007. Global molecular surveillance reveals novel Fusarium head blight species and trichothecene toxin diversity. Fungal Genet. Biol. 44:1191–204 [Google Scholar]
  117. Steinberg EB, Henderson A, Karpati A, Hoekstra M, Marano N. et al. 2006. Mysterious outbreaks of gastrointestinal illness associated with burritos supplied through school lunch programs. J. Food Protect. 69:1690–98 [Google Scholar]
  118. Strosnider H, Azziz-Baumgartner E, Banziger M, Bhat RV, Breiman R. et al. 2006. Workgroup report: public health strategies for reducing aflatoxin exposure in developing countries. Environ. Health Perspect. 114:1898–903 [Google Scholar]
  119. Studer-Rohr I, Schlatter J, Dietrich DR. 2000. Kinetic parameters and intraindividual fluctuations of ochratoxin A plasma levels in humans. Arch. Toxicol. 74:9499–510 [Google Scholar]
  120. Sugita-Konishi Y, Nakajiima T. 2010. Nivalenol: the mycology, occurrence, toxicology, analysis and regulation. Mycotoxins in Food, Feed and Bioweapons MV Rai, A Varma 253–73 Berlin/Heidelberg: Springer-Verlag [Google Scholar]
  121. Sun G, Wang S, Hu X, Su J, Huang T. et al. 2007. Fumonisin B1 contamination of home-grown corn in high-risk areas for esophageal and liver cancer in China. Food Addit. Contam. 24:2181–85 [Google Scholar]
  122. Sun G, Wang S, Hu X, Su J, Zhang Y. et al. 2011. Co-contamination of aflatoxin B(1) and fumonisin B(1) in food and human dietary exposure in three areas of China. Food Addit. Contam. A Chem. Anal. Control Expo. Risk Assess. 18:1–10 [Google Scholar]
  123. Sun LY, Li Q, Meng FG, Fu Y, Zhao ZJ, Wang LH. 2012. T-2 toxin contamination in grains and selenium concentration in drinking water and grains in Kaschin-Beck disease endemic areas of Qinghai Province. Biol. Trace Elem. Res. 150:371–75 [Google Scholar]
  124. Sun Z, Lu P, Gail MH, Pee D, Zhang Q. et al. 1999. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 30:379–83 [Google Scholar]
  125. Sydenham EW, Marasas WFO, Shephard GS, Thiel PG, Hirooka EY. 1992. Fumonisin concentrations in Brazilian feeds associated with field outbreaks of confirmed and suspected animal mycotoxicoses. J. Agric. Food Chem. 40:994–97 [Google Scholar]
  126. Szelenyi I, Herold H, Gothert M. 1994. Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents. J. Pharmacol. Toxicol. Methods 32:109–16 [Google Scholar]
  127. Takahashi M, Shibutani M, Sugita-Konishi Y, Aihara M, Inoue K. et al. 2008. A 90-day subchronic toxicity study of nivalenol, a trichothecene mycotoxin, in F344 rats. Food Chem. Toxicol. 46:125–35 [Google Scholar]
  128. Turesky RJ. 2005. Perspective: ochratoxin A is not a genotoxic carcinogen. Chem. Res. Toxicol. 18:71082–90 [Google Scholar]
  129. Turner PC, Moore SE, Hall AJ, Prentice AM, Wild CP. 2003. Modification of immune function through exposure to dietary aflatoxin in Gambian children. Environ. Health Perspect. 111:217–20 [Google Scholar]
  130. Turner PC, Collinson AC, Cheung YB, Gong Y, Hall AJ. et al. 2007. Aflatoxin exposure in utero causes growth faltering in Gambian infants. Int. J. Epidemiol. 36:1119–25 [Google Scholar]
  131. Turner PC, Flannery B, Isitt C, Ali M, Pestka J. 2012. The role of biomarkers in evaluating human health concerns from fungal contaminants in food. Nutr. Res. Rev. 25:162–79 [Google Scholar]
  132. Van der Zijden AS, Blanche Koelensmid WA, Boldingh J, Barrett CB, Ord WO, Philp J. 1962. Isolation in crystalline form of a toxin responsible for turkey x disease. Nature 195:1060–62 [Google Scholar]
  133. Van Rensburg SJ, Cook-Mozaffari P, Van Schalkwyk DJ, Van der Watt JJ, Vincent TJ, Purchase IF. 1985. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br. J. Cancer 51:713–26 [Google Scholar]
  134. Vatanasapt V, Martin N, Sriplung H, Chindavijak K, Sontipong S. et al. 1995. Cancer incidence in Thailand, 1988–1991. Cancer Epidemiol. Biomarkers Prev. 4:475–83 [Google Scholar]
  135. Wafa EW, Yahya RS, Sobh MA, Eraky I, El-Baz M. et al. 1998. Human ochratoxicosis and nephropathy in Egypt: a preliminary study. Hum. Exp. Toxicol. 17:124–29 [Google Scholar]
  136. Wang LY, Hatch M, Chen CJ, Levin B, You SL. et al. 1996. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan.. Int. J. Cancer 67:620–25 [Google Scholar]
  137. Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M. et al. 2002. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 181–182:43–47 [Google Scholar]
  138. Wild CP, Hudson GJ, Sabbioni G, Chapot B, Hall AJ. et al. 1992. Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in the Gambia, west Africa. Cancer Epidemiol. Biomarkers Prev. 1:229–34 [Google Scholar]
  139. Wogan GN, Kensler TW, Groopman JD. 2012. Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 29:249–57 [Google Scholar]
  140. Wogan GN, Newberne PM. 1967. Dose-response characteristics of aflatoxin b1 carcinogenesis in the rat. Cancer Res. 27:2370–76 [Google Scholar]
  141. Wu F. 2013. Aflatoxin exposure and chronic human diseases: estimates of burden of disease. In Aflatoxins: Finding Solutions for Improved Food Safety, ed. L Unnevehr, D Grace, Focus 20, Brief 3. Washington, DC: Int. Food Policy Res. Inst. http://www.ifpri.org/sites/default/files/publications/focus20.pdf [Google Scholar]
  142. Wu F, Munkvold GP. 2008. Mycotoxins in ethanol co-products: modeling economic impacts on the livestock industry. J. Agric. Food Chem. 56:3900–11 [Google Scholar]
  143. Wu F, Khlangwiset P. 2010. Evaluating the technical feasibility of aflatoxin risk reduction strategies in Africa. Food Addit. Contam. 27:658–76 [Google Scholar]
  144. Wu F, Stacy SL, Kensler TW. 2013. Global risk assessment of aflatoxins in maize and peanuts: Are regulatory standards adequately protective?. Toxicol. Sci. 135:251–59 [Google Scholar]
  145. Wu W, Bates MA, Bursian SJ, Flannery B, Zhou HR. et al. 2013a. Peptide YY3-36 and 5-hydroxytryptamine mediate emesis induction by trichothecene deoxynivalenol (vomitoxin). Toxicol. Sci. 133:186–95 [Google Scholar]
  146. Wu W, Bates MA, Bursian SJ, Link JE, Flannery BM. et al. 2013b. Comparison of emetic potencies of the 8-ketotrichothecenes deoxynivalenol, 15-acetyldeoxynivalenol, 3-acetyldeoxynivalenol, fusarenon X, and nivalenol. Toxicol. Sci. 131:279–91 [Google Scholar]
  147. Yan D, Kang P, Li Y, Yang J, Shen B. et al. 2011. Radiographic findings of Wistar rats fed with T-2 toxin and Kashin-Beck disease-affected diet. Int. J. Rheum. Dis. 14:92–97 [Google Scholar]
  148. Yan D, Kang P, Yang J, Shen B, Zhou Z. et al. 2010. The effect of Kashin-Beck disease-affected feed and T-2 toxin on the bone development of Wistar rats. Int. J. Rheum. Dis. 13:266–72 [Google Scholar]
  149. Yeh FC, Chang CL, Liu WS. 1986. Anesthesia management in malnutritional patients. Ma Zui Xue Za Zhi 24:216–21 [Google Scholar]
  150. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE. 1989. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res. 49:2506–9 [Google Scholar]
  151. Yoshizawa T. 1983. Trichothecenes—Chemical, Biological, and Toxicological Aspects (Developments in Food Science). Y Ueno 195–209 Tokyo, Japan: Kodansha Ltd. [Google Scholar]
  152. Young LG, McGirr L, Valli VE, Lumsden JH, Lun A. 1983. Vomitoxin in corn fed to young pigs. J. Anim. Sci. 57:655–64 [Google Scholar]
  153. Yu MW, Lien JP, Chiu YH, Santella RM, Liaw YF, Chen CJ. 1997. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J. Hepatol. 27:320–30 [Google Scholar]
  154. Zhai SS, Kimbrough RD, Meng B, Han JY, LeVois M. et al. 1990. Kashin-Beck disease: a cross-sectional study in seven villages in the People's Republic of China. J. Toxicol. Environ. Health 30:239–59 [Google Scholar]

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error